VBI Vaccines, Inc. (VBIV): Earnings per share for the last twelve months

The fundamental TTM net income per share metric for VBI Vaccines Inc. (VBIV) demonstrates yield dynamics, where -3.51 characterizes this valuation parameter. Production capacities for Hepatitis B vaccines in Canada and Israel support operational resilience. While VBI Vaccines Inc. (VBIV) previously attracted scientists with innovative platforms and options, the current sharp brain drain and contraction of the R&D sector create serious risks for the future.
VBI Vaccines Inc - analytical breakdowns and key metrics (VBIV)

Net income per share (TTM) reflects the portion of profit attributable to a single common share over the last four quarters. Calculating this by dividing total income by the number of shares allows for an assessment of real value generation efficiency. By analyzing the company's annual specific net income, an investor identifies the long-term profitability trend. For VBI Vaccines Inc. (VBIV), this metric is critical due to strict FDA oversight. Vaccine patents create a defensive barrier that determines future profit dynamics.